LINGOOD
833284
HENDERA
831152
Hanjia Design Group
300746
4
Guangdong Real-Design Intelligent Technology
301135
5
Fuxin Dare Automotive Parts
300473
US Stock MarketDetailed Quotes
CRSP CRISPR Therapeutics
- 44.400
- -0.110-0.25%
Close Feb 26 16:00 ET
- 44.600
- +0.200+0.45%
Post 19:49 ET
3.81BMarket Cap-10.23P/E (TTM)
46.000High43.970Low1.24MVolume44.880Open44.510Pre Close55.68MTurnover1.48%Turnover RatioLossP/E (Static)85.77MShares84.17052wk High1.97P/B3.73BFloat Cap36.52052wk Low--Dividend TTM83.93MShs Float220.200Historical High--Div YieldTTM4.56%Amplitude11.630Historical Low44.900Avg Price1Lot Size
CRISPR Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -90.54%35M | -82.50%35M | 0 | 0 | 0 | 84,762.39%370M | 3,333,233.33%200M | 0 | 44,203.80%70M | 56,079.78%100M |
| Operating revenue | -90.54%35M | -82.50%35M | --0 | --0 | --0 | 84,762.39%370M | 3,333,233.33%200M | --0 | 44,203.80%70M | 56,079.78%100M |
| Cost of revenue | -15.36%110.25M | 0 | -52.38%11.15M | 16.79%52.13M | 11.31%46.97M | 18.14%130.25M | 193.13%20M | -39.73%23.42M | 31.58%44.64M | 37.68%42.19M |
| Gross profit | -131.39%-75.25M | -80.56%35M | 52.38%-11.15M | -305.53%-52.13M | -181.24%-46.97M | 318.32%239.75M | 2,740.46%180M | 39.58%-23.42M | 175.12%25.36M | 289.73%57.81M |
| Operating expense | -15.35%391.32M | -9.81%99.59M | -9.19%98.98M | -17.79%99.13M | -23.45%93.62M | -17.94%462.29M | -11.47%110.42M | -24.11%108.99M | -19.34%120.59M | -15.95%122.3M |
| Selling and administrative expenses | -4.18%72.98M | 9.98%18.12M | -4.77%17.42M | 2.36%19.48M | -19.71%17.95M | -25.67%76.16M | -22.16%16.48M | -32.26%18.29M | -27.56%19.03M | -20.20%22.36M |
| -General and administrative expense | -4.18%72.98M | 9.98%18.12M | -4.77%17.42M | 2.36%19.48M | -19.71%17.95M | -25.67%76.16M | -22.16%16.48M | -32.26%18.29M | -27.56%19.03M | -20.20%22.36M |
| Research and development costs | -17.21%320.65M | -13.65%82.16M | -9.41%82.16M | -21.06%80.17M | -23.78%76.17M | -16.10%387.33M | -8.12%95.14M | -22.23%90.7M | -17.58%101.56M | -15.48%99.94M |
| Other operating expenses | -91.87%-2.31M | ---691K | ---602K | ---517K | ---504K | -58.27%-1.21M | ---- | ---- | ---- | ---- |
| Operating profit | -109.66%-466.57M | -192.82%-64.59M | 16.83%-110.13M | -58.85%-151.26M | -118.01%-140.59M | 66.94%-222.54M | 152.90%69.58M | 27.40%-132.41M | 48.04%-95.22M | 63.35%-64.49M |
| Net non-operating interest income expense | ||||||||||
| Other net income (expense) | 44.68%103.9M | 39.91%27.98M | 21.25%25.06M | 42.01%26.14M | 94.00%24.72M | 216.91%71.82M | 74.04%20M | 184.57%20.67M | 419.36%18.41M | 3,410.19%12.74M |
| Other non- operating income (expenses) | 44.68%103.9M | 39.91%27.98M | 21.25%25.06M | 42.01%26.14M | 94.00%24.72M | 216.91%71.82M | 74.04%20M | 184.57%20.67M | 419.36%18.41M | 3,410.19%12.74M |
| Income before tax | -140.62%-362.67M | -140.87%-36.61M | 23.87%-85.07M | -62.88%-125.12M | -123.92%-115.87M | 76.83%-150.72M | 174.62%89.58M | 36.19%-111.74M | 57.26%-76.82M | 70.53%-51.75M |
| Income tax | 24.20%3.59M | 200.43%700K | 112.62%876K | 39.44%1.29M | -45.15%724K | 988.62%2.89M | 102.46%233K | 171.65%412K | -84.91%923K | -63.41%1.32M |
| Net income | -138.43%-366.25M | -141.76%-37.31M | 23.37%-85.94M | -62.60%-126.41M | -119.71%-116.59M | 76.37%-153.61M | 180.80%89.35M | 35.75%-112.15M | 58.17%-77.74M | 70.39%-53.07M |
| Net income continuous Operations | -138.43%-366.25M | -141.76%-37.31M | 23.37%-85.94M | -62.60%-126.41M | -119.71%-116.59M | 76.37%-153.61M | 180.80%89.35M | 35.75%-112.15M | 58.17%-77.74M | 70.39%-53.07M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -138.43%-366.25M | -141.76%-37.31M | 23.37%-85.94M | -62.60%-126.41M | -119.71%-116.59M | 76.37%-153.61M | 180.80%89.35M | 35.75%-112.15M | 58.17%-77.74M | 70.39%-53.07M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -138.43%-366.25M | -141.76%-37.31M | 23.37%-85.94M | -62.60%-126.41M | -119.71%-116.59M | 76.37%-153.61M | 180.80%89.35M | 35.75%-112.15M | 58.17%-77.74M | 70.39%-53.07M |
| Basic earnings per share | -123.71%-4.34 | -138.94%-0.44 | 28.37%-1.01 | -52.04%-1.49 | -113.43%-1.43 | 76.79%-1.94 | 180.14%1.13 | 37.05%-1.41 | 59.17%-0.98 | 71.12%-0.67 |
| Diluted earnings per share | -123.71%-4.34 | -138.94%-0.44 | 28.37%-1.01 | -52.04%-1.49 | -113.43%-1.43 | 76.79%-1.94 | 180.14%1.13 | 37.05%-1.41 | 59.17%-0.98 | 71.12%-0.67 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Trending Stocks
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call